Is HYFT a good stock to buy right now?

Based on our 6-factor quantitative model, ImmunoPrecise Antibodies Ltd. (HYFT) receives a "Reduce" rating with a composite score of 39.7/100. It is ranked #2,496 out of 4,446 stocks. Key factor scores: Quality 41/100, Value 16/100, Momentum 50/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for HYFT?

ImmunoPrecise Antibodies Ltd. (HYFT) has a "Reduce" rating and 2-star score. The composite score of 39.7 ranks it #2,496 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is HYFT in?

ImmunoPrecise Antibodies Ltd. operates in the Healthcare sector (Pharmaceutical Products industry) with a market cap of $53 million. It is classified as a micro-cap stock.

Does HYFT pay a dividend?

HYFT does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is HYFT's P/E ratio?

P/E ratio data is not currently available for HYFT, which may indicate the company is not yet profitable.

How profitable is HYFT?

HYFT's quality factor score is 41/100. Gross margin: 67.0%. ROE: -511.9% vs sector average -43.5%. High margins suggest pricing power and competitive moats.

How is HYFT valued compared to peers?

HYFT's value factor score is 16/100 (higher = cheaper). Key multiples: . Trading at a premium relative to peers.

What is HYFT's debt level?

HYFT's debt-to-equity ratio is 0%. Sector average: 32%. Low leverage suggests conservative financial management.

HYFT has a beta of 1.45, meaning it amplifies market moves. Stability score: 17/100.

Does HYFT have high short interest?

HYFT's short interest factor score is 48/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

HYFT Stock Analysis: Top Micro-Cap Reduce (Score 39.7/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
HYFT	-4.46%	-6.14%	-17.69%	-41.21%	+166.83%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-4.40%	-9.74%	-18.03%	-40.85%	+137.31%	-	-	-
Alpha vs Sector	-3.11%	-6.48%	-13.88%	-36.37%	+157.63%	-	-	-

Metric	HYFT	Benchmark
P/E Ratio	-0.6x	-102%
EV/EBITDA	—	—
Price / Book	3.0x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
HYFT ImmunoPrecise Antibodies Ltd.	40	41	16	50	-	-511.9%	67.0%	-149.5%	-	0.0x	$53M

Key Ratio	TTM	2025	2024	2023	2022	2021	2020
Gross Margin %	0.7%	0.7%	0.6%	0.6%	0.6%	0.8%	0.7%
Operating Margin %	-1.7%	-1.7%	-1.4%	-1.3%	-0.8%	-0.4%	-0.3%
EBITDA Margin %	-1.4%	-1.4%	-1.1%	-1.0%	-0.6%	-0.2%	-0.1%
Net Margin %	-1.5%	-1.5%	-1.2%	-1.3%	-0.9%	-0.5%	-0.4%
FCF Margin %	-35.6%	-35.6%	-10.6%	-103.2%	-56.7%	45.9%	-
ROE %	-5.1%	-1.3%	-0.8%	-0.5%	-0.2%	-0.1%	-0.1%
ROA %	-2.7%	-0.7%	-0.4%	-0.3%	-0.2%	-0.1%	-0.2%
ROIC %	-204.6%	-204.6%	-75.6%	-44.0%	-27.9%	-4.6%	-10.0%

Line Item	TTM	2025	2024	2023	2022	2021	2020
	$15M	$15M	$15M	$15M	$15M	$14M	$8M
	$10M	$10M	$9M	$9M	$9M	$9M	$6M
Gross Margin	67.0%	67.0%	57.5%	56.0%	56.7%	82.0%	67.2%
	—	$4M	$3M	$9M	$6M	$2M	$317K
Depreciation	—	$4M	$4M	$5M	$3M	$3M	$2M
	-$24M	-$24M	-$21M	-$20M	-$13M	-$2M	-$3M
EBIT	-$24M	-$24M	-$21M	-$20M	-$13M	-$2M	-$3M
EBITDA	-$21M	-$21M	-$17M	-$16M	-$9M	-$2M	-$436K
Operating Margin	-166.0%	-166.0%	-138.9%	-134.3%	-81.8%	-38.1%	-33.4%
EBITDA Margin	-143.6%	-143.6%	-111.2%	-101.9%	-62.4%	-17.3%	-5.1%
	—	$205K	-$17K	$0	$0	$424K	$415K
	—	-$3M	-$2M	-$880K	$673K	$1M	-$246K
	-$22M	-$22M	-$19M	-$20M	-$13M	-$6M	-$4M
Net Margin	-149.5%	-149.5%	-124.5%	-128.5%	-86.3%	-52.1%	-41.4%
	-	-	-	-	-	$-0.37	$-0.26
Diluted EPS	-	-	-	-	-	$-0.37	$-0.26

ImmunoPrecise Antibodies Ltd. (HYFT) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does ImmunoPrecise Antibodies Ltd. Do?

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada. ImmunoPrecise Antibodies Ltd. (HYFT) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Jennifer L. Bath and employs approximately 80 people. With a market capitalization of $53M, HYFT is one of the notable companies in the Healthcare sector.

ImmunoPrecise Antibodies Ltd. (HYFT) Stock Rating — Reduce (April 2026)

As of April 2026, ImmunoPrecise Antibodies Ltd. receives a Reduce rating with a composite score of 39.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.HYFT ranks #2,496 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ImmunoPrecise Antibodies Ltd. ranks #319 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

HYFT Stock Price and 52-Week Range

ImmunoPrecise Antibodies Ltd. (HYFT) currently trades at $1.06. The stock lost $0.06 (5.4%) in the most recent trading session. The 52-week high for HYFT is $3.25, which means the stock is currently trading -67.3% from its annual peak. The 52-week low is $0.32, putting the stock 235.3% above its annual trough. Recent trading volume was 186K shares, suggesting relatively thin trading activity.

Is HYFT Overvalued or Undervalued? — Valuation Analysis

ImmunoPrecise Antibodies Ltd. (HYFT) carries a value factor score of 16/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.00x, versus the sector average of 2.75x. The price-to-sales ratio is 0.88x, compared to 1.66x for the average Healthcare stock.

At current multiples, ImmunoPrecise Antibodies Ltd. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

ImmunoPrecise Antibodies Ltd. Profitability — ROE, Margins, and Quality Score

ImmunoPrecise Antibodies Ltd. (HYFT) earns a quality factor score of 41/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -511.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -272.1% versus the sector average of -33.1%.

On a margin basis, ImmunoPrecise Antibodies Ltd. reports gross margins of 67.0%, compared to 71.5% for the sector. The operating margin is -166.0% (sector: -66.1%). Net profit margin stands at -149.5%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

HYFT Debt, Balance Sheet, and Financial Health

ImmunoPrecise Antibodies Ltd. has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $0. Cash and equivalents stand at $8M.

HYFT has a beta of 1.45, meaning it is more volatile than the broader market — a $10,000 investment in HYFT would be expected to move 45.1% more than the S&P 500 on any given day. The stability factor score for ImmunoPrecise Antibodies Ltd. is 17/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

ImmunoPrecise Antibodies Ltd. Revenue and Earnings History — Quarterly Trend

In TTM 2026, ImmunoPrecise Antibodies Ltd. reported revenue of $15M. Net income for the quarter was $-22M. Gross margin was 67.0%. Operating income came in at $-24M.

In FY 2025, ImmunoPrecise Antibodies Ltd. reported revenue of $15M. Net income for the quarter was $-22M. Gross margin was 67.0%. Revenue grew -4.0% year-over-year compared to FY 2024. Operating income came in at $-24M.

In FY 2024, ImmunoPrecise Antibodies Ltd. reported revenue of $15M. Net income for the quarter was $-19M. Gross margin was 57.5%. Revenue grew 0.1% year-over-year compared to FY 2023. Operating income came in at $-21M.

In FY 2023, ImmunoPrecise Antibodies Ltd. reported revenue of $15M. Net income for the quarter was $-20M. Gross margin was 56.0%. Revenue grew 0.8% year-over-year compared to FY 2022. Operating income came in at $-20M.

Over the past 7 quarters, ImmunoPrecise Antibodies Ltd. has demonstrated a growth trajectory, with revenue expanding from $8M to $15M. Investors analyzing HYFT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

HYFT Dividend Yield and Income Analysis

ImmunoPrecise Antibodies Ltd. (HYFT) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

HYFT Momentum and Technical Analysis Profile

ImmunoPrecise Antibodies Ltd. (HYFT) has a momentum factor score of 50/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 59/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 48/100 reflects moderate short selling activity.

HYFT vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ImmunoPrecise Antibodies Ltd. (HYFT) ranks #319 out of 838 stocks based on the Blank Capital composite score. This places HYFT in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing HYFT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full HYFT vs S&P 500 (SPY) comparison to assess how ImmunoPrecise Antibodies Ltd. stacks up against the broader market across all factor dimensions.

HYFT Next Earnings Date

No upcoming earnings date has been announced for ImmunoPrecise Antibodies Ltd. (HYFT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy HYFT? — Investment Thesis Summary

The quantitative profile for ImmunoPrecise Antibodies Ltd. suggests caution. The value score of 16/100 indicates premium valuation. High volatility (stability score 17/100) increases portfolio risk.

In summary, ImmunoPrecise Antibodies Ltd. (HYFT) earns a Reduce rating with a composite score of 39.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on HYFT stock.

Related Resources for HYFT Investors

Explore more research and tools: HYFT vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare HYFT head-to-head with peers: HYFT vs AZN, HYFT vs SLGL, HYFT vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q3 2026 Earnings Call Transcript

MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results

MindWalk Q3 Earnings Preview (NASDAQ:HYFT)

MindWalk Holdings Corp. (HYFT) Reports Q3 Loss, Lags Revenue Estimates

Stagwell (STGW) Q4 Earnings and Revenues Top Estimates

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks